FTC orders Baxter to divest rights in Claris deal
The Federal Trade Commission (FTC) has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.
In July, the FTC filed a complaint suggesting that Baxter’s proposed acquisition would probably decrease competition in the US market for antifungal agent fluconazole, in saline intravenous bags, as well as future competition in the US market for intravenous milrinone.
The order put forward by the commission, which follows a public comment period, instructs the parties to divest all of Claris’s rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to Renaissance Lakewood, a pharmaceutical company based in New Jersey.
Baxter will supply Renaissance with the relevant drugs for up to five years while also transferring the manufacturing technology to Renaissance.
The drugs in question dilate the blood vessels, lower blood pressure and allow blood to flow more easily through the cardiovascular system.
The FTC vote approving the final order was 2-0.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk